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Introduction {#bjs550121-sec-0005}
============

Breast‐conserving therapy (BCT) for invasive breast cancer combines wide local excision (WLE) with adjuvant radiotherapy and provides equivalent outcomes to mastectomy for early‐stage breast cancer[1](#bjs550121-bib-0001){ref-type="ref"}, [2](#bjs550121-bib-0002){ref-type="ref"}, [3](#bjs550121-bib-0003){ref-type="ref"}, [4](#bjs550121-bib-0004){ref-type="ref"}, [5](#bjs550121-bib-0005){ref-type="ref"}, [6](#bjs550121-bib-0006){ref-type="ref"}. Preservation of the breast has a number of advantages over mastectomy, including psychological benefits[7](#bjs550121-bib-0007){ref-type="ref"}, shorter operating times, less postoperative pain, and fewer clinically significant complications such as haematoma and seroma[8](#bjs550121-bib-0008){ref-type="ref"} [9](#bjs550121-bib-0009){ref-type="ref"}. A shorter recovery period allows earlier return to work and reduces the economic impact of the cancer treatment. The cosmetic outcome following WLE is generally superior to that achieved by mastectomy and reconstruction[10](#bjs550121-bib-0010){ref-type="ref"}.

Local recurrence represents a significant event for the patient. Data from the Early Breast Cancer Trialists\' Collaborative Group[11](#bjs550121-bib-0011){ref-type="ref"} suggest that avoidance of local recurrence reduces the rate of breast cancer death by 25 per cent. Local control in BCT can be attributed to two main factors: clear resection margins and adjuvant radiotherapy to the remaining breast, with the latter shown to reduce local recurrence by 19 per cent[12](#bjs550121-bib-0012){ref-type="ref"}. In 2014, the Society of Surgical Oncology and American Society for Radiation Oncology (SSO--ASTRO) published their updated consensus guideline[13](#bjs550121-bib-0013){ref-type="ref"} on margins, for breast‐conserving surgery with whole breast irradiation for invasive disease, in response to a meta‐analysis[14](#bjs550121-bib-0014){ref-type="ref"} of data on surgical margins and local recurrence following BCT in 28 162 women. This study[14](#bjs550121-bib-0014){ref-type="ref"} found a median local recurrence rate of 5·3 per cent and showed that, although the risk of local recurrence was doubled in patients with positive margins, as long as there was 'no ink on tumour' wider margins did not reduce the risk. The SSO--ASTRO consensus guideline[13](#bjs550121-bib-0013){ref-type="ref"} on margins for BCT now recommends the use of no ink on tumour as the standard for an adequate margin in invasive breast cancer.

In the UK and Ireland, the 2016 National Margins Audit[15](#bjs550121-bib-0015){ref-type="ref"} found large variation in margin policy and re‐excision rates across breast units. Although the National Institute for Health and Care Excellence defines a margin clearance of 2 mm for ductal carcinoma *in situ* (DCIS)[16](#bjs550121-bib-0016){ref-type="ref"}, the Association of Breast Surgery recommends minimum margins of 1 mm for both DCIS and invasive disease[17](#bjs550121-bib-0017){ref-type="ref"}. Lack of margin consensus and resultant variation in practice across the UK and Ireland raises a number of concerns. Excising too much tissue may result in poor cosmesis, which can be exacerbated by adjuvant radiotherapy. Some women may be subjected to unnecessary additional surgery. Margin re‐excision may further worsen cosmesis as well as contribute to the emotional burden of cancer treatment and increase the risk of postoperative complications. Additional procedures for margin clearance and to correct poor cosmesis, such as lipofilling, increase healthcare costs[18](#bjs550121-bib-0018){ref-type="ref"}.

In light of the recently published SSO--ASTRO guidelines[13](#bjs550121-bib-0013){ref-type="ref"}, the primary aim of this study was to explore clinical, surgical and tumour‐related factors associated with local recurrence risk. The secondary aim was to assess the role of margin re‐excision in reducing the risk of local recurrence.

Methods {#bjs550121-sec-0006}
=======

This project was approved as a service evaluation by the Royal Marsden NHS Trust, protocol BR068. A database of patients with invasive breast cancer treated by BCT between 8 January 1997 and 3 January 2007 was generated with the collaboration of clinicians in the Breast Unit and the Department of Information Technology and Statistics at the Royal Marsden NHS Trust. Data collection comprised patient demographics, surgical details, tumour characteristics, adjuvant therapy and clinical outcomes, including local recurrence, distant metastasis, breast cancer‐related and all‐cause mortality. Margin status was defined as involved, clear (1 mm or more), close (less than 1 mm but no ink on tumour), reaches (ink on tumour) and clear after re‐excision. During the study interval, the institutional policy was to accept margins of 1 mm or greater. However, individual case discussion by the multidisciplinary team resulted in some cases where margins were close (under 1 mm but not reaching ink) being accepted.

Tumour characteristics recorded in the original histology reports were retrieved from the hospital\'s electronic patient records. Local recurrences were identified by examining all histology reports indicating further surgery and excision of recurrent tumour, and by reviewing all follow‐up clinic letters. A true local recurrence was determined by the presence of a subsequent carcinoma of similar biology (grade and receptor status) within the same quadrant of the breast as the first presenting carcinoma. Any new carcinomas within the same breast that did not fulfil the above criteria were considered new primary lesions.

Statistical analysis {#bjs550121-sec-0007}
--------------------

The Cox proportional hazard regression model was used to compare the hazards of patients in each group, using univariable models. A two‐sided 5 per cent α level was used to assess statistically significant difference in the models. A multivariable model was used to identify the independent predictors of local recurrence and disease‐free survival. Variables found to be significant at *P* ≤ 0·200 in the univariable model were included in a forward stepwise method, which was used to fit the multivariable model. SPSS® version 16.0 (IBM, Armonk, New York, USA) was used for statistical analysis.

The Kaplan--Meier method was used to calculate the time to local recurrence and disease‐free survival from the date of wide local excision. Diagnosis of local recurrence in the ipsilateral breast was the defining event for time to local recurrence; axillary recurrence, supraclavicular fossa (SCF) recurrence, metastasis and death without local recurrence were censored as independent events. For disease‐free survival, defining events included local recurrence, axillary recurrence, SCF recurrence, metastasis and death from any cause. Patients who were alive and disease‐free or lost to follow‐up were censored at the date of their last follow‐up or upon discharge.

Results {#bjs550121-sec-0008}
=======

Data were collected on 1440 women who had BCT during the study period. Some 253 women were excluded from further analysis because their initial surgery had been performed at a different hospital and clinical data from the referring hospital could not be accessed. A further 66 women were excluded because they did not receive radiotherapy as part of BCT. Seventy‐six patients had bilateral cancers and only one record (first surgery, or right breast if on the same date) was retained for the purposes of analysis. The median age of the 1045 remaining women was 54 (range 18--86) years. Margins were clear in 798 patients, and 110 had close margins. There was ink on tumour in 137 but, of this group, 122 women had subsequent re‐excision of margins, leaving 15 patients with ink on tumour. Patient and tumour characteristics, and surgical factors (type of axillary procedure and margin status) are presented in *Table*  [1](#bjs550121-tbl-0001){ref-type="table"}.

###### 

Patient and tumour characteristics

                                                    No. of patients (*n* = 1045)
  ------------------------------------------------ ------------------------------
  Axillary procedures                                        980 (93·8)
  Sentinel node biopsies                                        390
  Axillary sampling                                              29
  Axillary dissection                                           561
  Tumour type                                      
  Invasive ductal carcinoma                                  892 (85·4)
  Invasive lobular carcinoma                                 104 (10·0)
  Mixed invasive ductal and lobular carcinoma                 32 (3·1)
  Other[\*](#bjs550121-note-0002){ref-type="fn"}              17 (1·6)
  Lymphovascular invasion                          
  Yes                                                        333 (31·9)
  No                                                         712 (68·1)
  ER status                                        
  Positive                                                   881 (84·3)
  Negative                                                   164 (15·7)
  Excision margin                                  
  Clear (≥ 1 mm)                                             798 (76·4)
  Close (\< 1 mm)                                            110 (10·5)
  Reaches                                                     15 (1·4)
  Re‐excision                                                122 (11·7)

Values in parentheses are percentages.

Includes invasive mucinous, micropapillary, medullary carcinoma. ER, oestrogen receptor.

Median follow‐up for this study was 89 (range 4--196) months. Ninety‐seven (9·3 per cent) of the women died from their breast cancer (*Table*  [2](#bjs550121-tbl-0002){ref-type="table"}). Some 81·6 per cent remained disease‐free, 5·0 per cent relapsed first with local recurrence, and 11·2 per cent of patients developed metastatic disease. In women who relapsed, the overall mortality rate was 50·5 per cent. This varied with type of relapse; the mortality rate was 60 per cent in women who developed local recurrence first. There was a significantly greater risk of death from all causes in women with local recurrence compared with that in women with no local recurrence (46 per cent (24 of 52) *versus* 14·4 per cent (142 of 988) respectively; *P* \< 0·001), as well as a significantly greater risk of breast cancer‐related death (42 per cent (22 of 52) *versus* 7·3 per cent (72 of 988) respectively; *P* \< 0·001).

###### 

Type of disease relapse and breast cancer‐specific death

                           No. of patients   Breast cancer‐specific death
  ----------------------- ----------------- ------------------------------
  Total no. of patients         1045                   97 (9·3)
  Disease‐free               853 (81·6)                  n.a.
  Relapse (all types)        192 (18·4)               97 (50·5)
  Local recurrence            52 (5·0)                 31 (60)
  Axillary recurrence         15 (1·4)                  8 (53)
  SCF recurrence               8 (0·8)                  3 (38)
  Metastasis                 117 (11·2)               67 (57·3)

Values in parentheses are percentages. n.a., Not applicable; SCF, supraclavicular fossa.

The results of the univariable analysis of local recurrence are presented in *Table*  [3](#bjs550121-tbl-0003){ref-type="table"}. Women with ink on tumour were almost five times as likely as those with clear margins to develop local recurrence (hazard ratio (HR) 4·86; *P* = 0·009). Women with close margins had the same risk of local recurrence as women who had clear margins at initial surgery (HR 1·03; *P* = 0·954). Despite undergoing margin re‐excision and deemed to be clear, women who had re‐excision had double the risk of local recurrence compared with women with clear margins at primary surgery (HR 2·50; *P* = 0·005). In those who underwent re‐excision, the finding of residual disease in the re‐excision shaves was not associated with local recurrence (*P* = 1·000).

###### 

Cox univariable analysis of local recurrence

                                                                     *n*    Local recurrence events   Hazard ratio[\*](#bjs550121-note-0004a){ref-type="fn"}   *P*
  ------------------------------------------------------------------ ------ ------------------------- -------------------------------------------------------- -------
  Age, continuous[†](#bjs550121-note-0004b){ref-type="fn"}           1045   57 (5·5)                  0·97 (0·95, 1·00)                                        0·022
  Age (years)[†](#bjs550121-note-0004b){ref-type="fn"}                                                                                                         
  \< 50                                                              346    27 (7·8)                  1·66 (1·00, 2·80)                                        0·056
  ≥ 50                                                               699    30 (4·3)                  1·00 (reference)                                         
  Tumour size, continuous                                            1039   56 (5·4)                  1·02 (1·00, 1·04)                                        0·032
  Tumour size (cm)                                                                                                                                             
  ≤ 2                                                                667    31 (4·6)                  1·00 (reference)                                         0·098
  \> 2                                                               372    25 (6·7)                  1·56 (0·92, 2·64)                                        
  Excision margin                                                                                                                                              
  Clear                                                              798    36 (4·5)                  1·00 (reference)                                         0·004
  Reaches                                                            15     3 (20)                    4·86 (1·49, 15·79)                                       0·009
  Re‐excision                                                        122    13 (10·7)                 2·50 (1·32, 4·72)                                        0·005
  Close                                                              110    5 (4·5)                   1·03 (0·40, 2·62)                                        0·954
  Tumour grade[‡](#bjs550121-note-0004c){ref-type="fn"}                                                                                                        
  1                                                                  160    3 (1·9)                   1·00 (reference)                                         0·016
  2                                                                  463    22 (4·8)                  2·66 (0·80, 8·88)                                        0·112
  3                                                                  420    32 (7·6)                  4·47 (1·37, 14·61)                                       0·013
  Lymphovascular invasion[‡](#bjs550121-note-0004c){ref-type="fn"}                                                                                             
  No                                                                 699    35 (5·0)                  1·00 (reference)                                         0·608
  Yes                                                                333    21 (6·3)                  1·15 (0·67, 1·98)                                        
  ER status                                                                                                                                                    
  Negative                                                           164    16 (9·8)                  2·28 (1·28, 4·06)                                        0·005
  Positive                                                           881    41 (4·7)                  1·00 (reference)                                         
  Final node group                                                                                                                                             
  Negative                                                           637    36 (5·7)                  1·00 (reference)                                         0·079
  Positive (N1)                                                      266    10 (3·8)                  0·63 (0·31, 1·26)                                        
  Positive (N2--N3)                                                  82     4 (5)                     0·93 (0·33, 2·60)                                        
  Unknown                                                            60     7 (12)                    2·25 (1·00, 5·06)                                        

Values in parentheses are percentages unless indicated otherwise;

values in parentheses are 95 per cent confidence intervals.

Age and tumour size were analysed as continuous and then as categorical variables.

Missing data for this variable.

ER, oestrogen receptor; N1, one to three nodes involved; N2, four to nine nodes involved; N3, ten or more nodes involved.

Each millimetre increase in tumour size increased the hazard of local recurrence by 1·02 (*P* = 0·032). Conversely, each year increase in age reduced the hazard by 0·03 (*P* = 0·022). Oestrogen receptor (ER)‐negative tumours were more likely to be associated with local recurrence than ER‐positive tumours (HR 2·28; *P* = 0·005). Local recurrence was more likely in grade 3 tumours (HR 4·47; *P* = 0·013). Both lymphovascular invasion and final node group were not associated with an increased risk of LR (*P* = 0·608 and *P* = 0·079 respectively) (*Table*  [3](#bjs550121-tbl-0003){ref-type="table"}).

In a multivariable model incorporating age, tumour size, excision margin status, grade, ER status and final node grouping, only involved excision margin and ER negativity predicted local recurrence (*Table*  [4](#bjs550121-tbl-0004){ref-type="table"}).

###### 

Cox multivariable analysis of local recurrence

                    Hazard ratio         *P*
  ----------------- -------------------- -------
  Excision margin                        
  Clear             1·00 (reference)     0·002
  Reaches           4·79 (1·47, 15·59)   0·009
  Re‐excision       2·70 (1·43, 5·13)    0·002
  Close             1·08 (0·42, 2·76)    0·873
  ER status                              
  Negative          2·41 (1·35, 4·31)    0·003
  Positive          1·00 (reference)     

Values in parentheses are 95 per cent confidence intervals. Margins were defined as clear (over 1 mm), reaches (ink on tumour), re‐excision (deemed clear after re‐excision) and close (less than 1 mm but no ink on tumour). ER, oestrogen receptor.

Kaplan--Meier curves of time from BCT to local recurrence for excision margin categories and ER status are shown in *Figs*  [1](#bjs550121-fig-0001){ref-type="fig"} and [2](#bjs550121-fig-0002){ref-type="fig"} respectively. Patients known to be alive and those lost to follow‐up were censored at the time of last follow‐up or discharge from the clinic. There was no difference in local recurrence between women with clear margins and those with close margins (*Fig*. [1](#bjs550121-fig-0001){ref-type="fig"}). In contrast, patients who had re‐excision of margins had an increased risk of local recurrence. Women with involved margins had the highest risk of local recurrence; this difference was most marked in the first 100 months after surgery, after which there were very few new events. Kaplan--Meier curves for ER status showed a higher local recurrence risk for ER‐negative breast cancers (*Fig*. [2](#bjs550121-fig-0002){ref-type="fig"}). Local recurrence occurred within the first 100 months after surgery for ER‐negative cancers in contrast to ER‐positive tumours, which demonstrated local recurrence events at regular intervals over 200 months.

![Kaplan--Meier curves of time to local recurrence according to margin status. WLE, wide local excision](BJS5-3-161-g001){#bjs550121-fig-0001}

![Kaplan--Meier curves of time to local recurrence according to oestrogen receptor status. ER, oestrogen receptor; WLE, wide local excision. Correction Note: the y‐axis for Figures 1 and 2 has been amended since first published on 26 December](BJS5-3-161-g002){#bjs550121-fig-0002}

Discussion {#bjs550121-sec-0009}
==========

In line with previous studies[13](#bjs550121-bib-0013){ref-type="ref"} [19](#bjs550121-bib-0019){ref-type="ref"}, [20](#bjs550121-bib-0020){ref-type="ref"}, the univariable analysis performed here shows an association between local recurrence and young age, large tumour size, higher grade, involved margins and ER negativity. In multivariable analysis, only two variables, margin status and ER status, remained significantly associated with local recurrence. As expected, women with involved margins had the highest risk of local recurrence and were almost five times as likely to develop local recurrence compared with those with clear margins. This difference was most marked in the first 100 months after BCT, with very few events after this time.

No difference in local recurrence was seen in women with clear margins and close margins. Although there is no clear consensus regarding acceptable margin width in the UK, these findings are in line with the SSO--ASTRO guideline[13](#bjs550121-bib-0013){ref-type="ref"} on adequate margin width in BCT. This American guideline is defined by the use of no ink on tumour as the standard for adequate margin in invasive cancer, and was introduced following the publication of a meta‐analysis of 33 studies on 28 162 patients.

An important new finding in the present study is that margin re‐excision confers only partial protection from local recurrence. Women who initially had involved margins and subsequently underwent margin re‐excision still had twice the risk of local recurrence compared with women who had clear margins at primary surgery. Furthermore, similar local recurrence rates were seen in women with residual disease in their re‐excision shaves and those who had no residual disease in the new re‐excision margin. An explanation is that the imprecise nature of margin re‐excisions can miss residual disease, and therefore those deemed to have clear margins after re‐excision in fact still had residual disease. Steps should be taken to improve the accuracy of margin re‐excision. Ideally, such surgery should be performed by the same surgeon who, in conjunction with pathology colleagues, should apply considerable effort in identifying, orienting and examining the surgical cavity and specimens. The technical challenges of returning to a previous operative site for margin clearance include failure to identify the previous cavity accurately and missing further disease by taking inadequate or inaccurate margin shavings. A study[21](#bjs550121-bib-0021){ref-type="ref"} that compared immediate re‐excision with delayed re‐excision in wide local excisions with positive margins found almost twice as much residual disease in the early re‐excision group (*P* \< 0·001) and supports early return to theatre before significant local repair mechanisms are established. Combined, all these issues highlight the significance of achieving clear margins at the time of the primary operation.

In 2017, the UK National Margins Audit[15](#bjs550121-bib-0015){ref-type="ref"} found a margin re‐excision rate of 17·2 (range 0--41) per cent. The study also found[22](#bjs550121-bib-0022){ref-type="ref"} that the current standard method of intraoperative margin assessment is specimen X‐ray (used by 96 per cent of participating UK breast units) and that patients with DCIS, invasive lobular carcinoma, higher‐grade disease, lower BMI and smaller breast cup size are at higher risk of margin re‐excision. In that study, the majority of margin re‐excisions took place for involved rather than for close margins.

Achieving complete excision in BCT without the need for re‐excision lowers local recurrence rates, enhances patient experience and reduces healthcare costs. Patients at increased risk of margin involvement should be identified and counselled appropriately when making their surgery choice. Studies have shown that patients with DCIS are at increased risk of margin re‐excision[23](#bjs550121-bib-0023){ref-type="ref"} [24](#bjs550121-bib-0024){ref-type="ref"}, and that underestimation of tumour size by current imaging techniques is a major factor associated with incomplete excision[25](#bjs550121-bib-0025){ref-type="ref"}. The accuracy of preoperative tumour size measurements may be improved by employing additional imaging modalities such as digital tomosynthesis and MRI. Discrepancies between preoperative imaging and postoperative histological tumour size should be identified and preoperative images reviewed. The current standard for intraoperative margin assessment using specimen X‐ray suffers from poor pooled diagnostic accuracy[26](#bjs550121-bib-0026){ref-type="ref"}. New intraoperative methods of assessing margins are being developed (for example MarginProbe®, Dune Medical Devices, Framingham, Massachusetts, USA[27](#bjs550121-bib-0027){ref-type="ref"}; ClearEdge™ (LS BioPath, Saratoga, California, USA[28](#bjs550121-bib-0028){ref-type="ref"}; and Rapid Evaporative Ionization Mass Spectrometry™ (REIMS™) iKnife™, Waters Corporation, Milford, Massachusetts, USA[29](#bjs550121-bib-0029){ref-type="ref"}) and will need to be evaluated formally in clinical trials.

Although the pathophysiology of local recurrence is not fully understood, it is generally recognized that there are two distinct types: recurrences that arise in the residual organ not involved in the surgery for the primary tumour, and scar recurrences that develop at the site of the previous tumour resection[30](#bjs550121-bib-0030){ref-type="ref"}. Field cancerization, in which there are genetically altered but microscopically normal cells, may offer an explanation for *in situ* recurrences, whereas scar recurrences can be accounted for by the presence of minimal residual disease[31](#bjs550121-bib-0031){ref-type="ref"}. Lesions that form *in situ* recurrences may not be apparent at histopathological examination, but can be detected by molecular analyses for phenotypic, genetic or epigenetic alterations, which include *p53* mutations, loss of heterozygosity, microsatellite instability, DNA methylation and integrated viral DNA. Studies[32](#bjs550121-bib-0032){ref-type="ref"} [33](#bjs550121-bib-0033){ref-type="ref"} have confirmed such changes at increasing distances from the wide local excision site. In the context of broader field change, concentrating on the immediate surrounds of the tumour alone accounts only partially for local recurrence risk. In the present study, the local recurrence rate of 5·0 per cent is in line with the 2014 meta‐analysis[14](#bjs550121-bib-0014){ref-type="ref"} of margins and local recurrence, which found a median rate of 5·3 per cent. This residual local recurrence rate of 5·0 per cent in the presence of microscopic clearance provides additional support for the field effect. In breast cancer, cells affected by field change are subjected to similar environmental carcinogens such as oestrogen. For ER‐positive cancers, adjuvant endocrine treatment alters the non‐tumour breast as well as the tumour bed environment and generates conditions less favourable to local disease relapse[34](#bjs550121-bib-0034){ref-type="ref"}, [35](#bjs550121-bib-0035){ref-type="ref"}, [36](#bjs550121-bib-0036){ref-type="ref"}. However, the increased likelihood of local recurrence in ER‐negative cancers seen in the present study, and other studies[37](#bjs550121-bib-0037){ref-type="ref"}, [38](#bjs550121-bib-0038){ref-type="ref"}, [39](#bjs550121-bib-0039){ref-type="ref"} showing increased relapse in triple‐negative cancers even following mastectomy, suggest that other variables such as chemokines and growth factors must also contribute to local relapse. Because of the early study period (1997--2007), there were insufficient retrospective data to assess the effect of progesterone receptor and human epidermal growth factor receptor 2 on local recurrence. Prospective studies are indicated to investigate the impact of these receptors and other methods of tumour profiling such as Ki‐67 and Oncotype DX® (Genomic Health, Redwood City, California, USA) testing on local recurrence in a UK cohort.

Although the mechanisms that underpin local recurrence after BCT are multifactorial, this study reinforces the importance of complete margin clearance and ER status. Narrow margin widths, even if less than 1 mm, confer equivalent local control compared with wider margins. The improvement in outcome is attributed to better adjuvant therapies in an era of aromatase inhibitors, taxanes and biological therapy, along with more consistent delivery of radiotherapy. Further reduction in local recurrence rates in the future should be seen if complete margin clearance can be achieved at the time of primary surgery.
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